Werewolf Therapeutics (NASDAQ:HOWL) Receives Outperform Rating from Wedbush

Werewolf Therapeutics (NASDAQ:HOWL)‘s stock had its “outperform” rating restated by equities researchers at Wedbush in a note issued to investors on Wednesday, Marketbeat Ratings reports. They currently have a $8.00 target price on the stock.

A number of other analysts have also issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of Werewolf Therapeutics in a report on Wednesday. JMP Securities lowered their price target on Werewolf Therapeutics from $12.00 to $4.00 and set a “market outperform” rating for the company in a report on Tuesday, January 14th.

Werewolf Therapeutics Stock Down 1.6 %

Shares of NASDAQ:HOWL opened at $1.21 on Wednesday. Werewolf Therapeutics has a 1 year low of $1.03 and a 1 year high of $6.89. The business has a 50 day simple moving average of $1.36 and a two-hundred day simple moving average of $1.82. The firm has a market capitalization of $53.92 million, a PE ratio of -0.79 and a beta of 0.37. The company has a debt-to-equity ratio of 0.29, a current ratio of 10.10 and a quick ratio of 10.10.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its earnings results on Tuesday, March 11th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.03). Werewolf Therapeutics had a negative net margin of 578.80% and a negative return on equity of 58.83%. On average, equities analysts predict that Werewolf Therapeutics will post -1.56 EPS for the current year.

Institutional Trading of Werewolf Therapeutics

A number of hedge funds have recently bought and sold shares of HOWL. PFM Health Sciences LP lifted its holdings in Werewolf Therapeutics by 4.9% during the third quarter. PFM Health Sciences LP now owns 3,398,747 shares of the company’s stock worth $7,205,000 after buying an additional 157,673 shares during the period. Deutsche Bank AG lifted its holdings in Werewolf Therapeutics by 450.7% during the fourth quarter. Deutsche Bank AG now owns 101,626 shares of the company’s stock worth $150,000 after buying an additional 83,172 shares during the period. State Street Corp lifted its holdings in Werewolf Therapeutics by 12.4% during the third quarter. State Street Corp now owns 476,439 shares of the company’s stock worth $1,010,000 after buying an additional 52,528 shares during the period. Levin Capital Strategies L.P. purchased a new stake in Werewolf Therapeutics during the fourth quarter worth $74,000. Finally, JPMorgan Chase & Co. lifted its holdings in Werewolf Therapeutics by 372.4% during the fourth quarter. JPMorgan Chase & Co. now owns 62,928 shares of the company’s stock worth $93,000 after buying an additional 49,608 shares during the period. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.